Benitec Biopharma (BNTC) Income towards Parent Company (2019 - 2025)

Benitec Biopharma has reported Income towards Parent Company for 7 years, with the latest figure at -$28.2 million in Q4 2025.

• Quarterly Income towards Parent Company rose 99.73% year-over-year to -$28.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$29.6 billion (down 64.51% YoY) and the FY2025 annual result came in at -$7.8 billion, down 228.5% from the prior year.
• Income towards Parent Company improved to -$28.2 million in Q4 2025 per BNTC's latest filing, from -$17.4 billion in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$3.6 million in Q1 2022 and troughed at -$17.4 billion in Q3 2025.
• A 5-year average of -$2.4 billion and a median of -$8.3 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company slumped 78152.51% in 2024, then surged 99.73% in 2025.
• Over 5 years, Income towards Parent Company stood at -$5.0 million in 2021, then fell by 27.07% to -$6.3 million in 2022, then tumbled by 187.36% to -$18.2 million in 2023, then sank by 57110.74% to -$10.4 billion in 2024, then soared by 99.73% to -$28.2 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$28.2 million, -$17.4 billion, and -$10.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.